We also discuss specific drugs such as resmetiron, fibroblast growth-factor 21 analogs, and lanifibranor, as these are currently undergoing phase 3 clinical trials and showing great promise treating patients suffering from MASLD. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.